

Commercialization Decision Guide v2.0

TCRLAS Refinement v2.0 | Working methodology | 15 October 2026

Definition and boundaries

TCRLAS assigns demonstrated milestone level independently. CVA evaluates forward-looking commercial viability. CDA authorizes a specific next action. Launch authorization is an additional, separately documented decision. Neither scores nor charts grant permission to market healthcare offerings.

Evidence and uncertainty

Date all evidence; identify evaluator, source, verification status, jurisdiction, scope and confidence. NE means not evaluated; zero is a justified adverse score, never a substitute for missing information.

Scoring policy

Scores 0–6 are ordinal evidence anchors. Do not interpret the arithmetic mean as probability or validated investment return. No required CVA or HSE numeric threshold controls advance or launch. Record blockers separately.

Preservation

Keep nine original TCRLAS milestones and their minimum conditions unchanged. Preserve legacy TCI as experimental and do not apply it automatically to new CVA scores.

Required inputs

Verified TCRLAS level, five CVA scores and evidence, healthcare extension where applicable, scope of next milestone, commercialization route, risk/blocker register, budgets, owners, options and opportunity costs.

Decision sequence

A Verify evidence and assessment scope. B Screen blockers affecting PROPOSED action. C Review opportunity and economics. D Verify execution resources for specific milestone. E Consider alternatives. F Authorize and record decision.

ADVANCE

Authorize only a bounded next milestone with success test, cost ceiling, owner, deadline and review date; does not automatically permit launch.

IMPROVE

Repair a known remediable gap and specify 1–3 evidence-producing tasks.

PIVOT

Test a materially different product, market, service delivery route or business model.

HOLD FOR EVIDENCE

Do not make decision until specified verifiable evidence is obtained. Name owner and review date.

STOP

Cease the evaluated route when unresolvable blocker or unattractive returns/risks justify doing so; preserve alternative research/licensing routes where useful.

Governance

Independent reviewer for consequential decisions where feasible; document dissent, verified versus claimed evidence, decision authority and reevaluation trigger.

Decision record template

Project | assessed offering and jurisdiction | date | TCRLAS and proof | CVA M/C/E/X/R evidence | HSE H1–H5 if applicable | blocker and applicability | next milestone | option chosen | economics | owner | authorization | deadline | independent review.

STATUS: PROPOSED WORKING DRAFT — not externally validated.